Clinical Trials Logo

Chronic Cough clinical trials

View clinical trials related to Chronic Cough.

Filter by:

NCT ID: NCT03696108 Completed - Chronic Cough Clinical Trials

A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)

Start date: October 31, 2018
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the safety of two doses of gefapixant (MK-7264) in Japanese adult participants with refractory or unexplained chronic cough.

NCT ID: NCT03639727 Completed - Chronic Cough Clinical Trials

Cough in Eastern and Central Finland

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

Comparison of citric acid and mannitol cough provocation tests among subjects with chronic cough and healthy volunteers.

NCT ID: NCT03622216 Completed - Chronic Cough Clinical Trials

A Dose Escalation Study of Bradanicline in Refractory Chronic Cough

Start date: November 5, 2018
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, crossover, dose escalation study of bradanicline in subjects with chronic cough

NCT ID: NCT03482713 Completed - Chronic Cough Clinical Trials

Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)

Start date: March 16, 2018
Phase: Phase 2
Study type: Interventional

This estimation study (no hypotheses) will evaluate the safety, tolerability, and efficacy of gefapixant (MK-7264) in Japanese adult participants with unexplained or refractory chronic cough.

NCT ID: NCT03449147 Completed - Chronic Cough Clinical Trials

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)

Start date: March 15, 2018
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period, and to determine the safety and tolerability of gefapixant. The primary hypothesis is that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.

NCT ID: NCT03449134 Completed - Chronic Cough Clinical Trials

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)

Start date: March 14, 2018
Phase: Phase 3
Study type: Interventional

The main objectives of this study will be to evaluate the efficacy of gefapixant in reducing cough frequency as measured over a 24-hour period at Week 12, and to evaluate the safety and tolerability of gefapixant. The primary hypothesis is that at least one gefapixant dose is superior to placebo in reducing coughs per hour (over 24 hours) at Week 12.

NCT ID: NCT03172130 Completed - OSA Clinical Trials

Sham CPAP vs. Straight CPAP for Chronic Cough

Start date: October 13, 2014
Phase: N/A
Study type: Interventional

Chronic cough is an important clinical problem in primary care and sub-specialty practice. Besides the distress experienced by patients with chronic cough, significant healthcare resources are expended to understand the role of gastroesophageal reflux, asthma and post-nasal drip in understanding their contribution to cough. Obstructive sleep apnea (OSA) is common in patients with chronic cough. More importantly, treatment of OSA with continuous positive airway pressure (CPAP) has led to improvement in cough for chronic cough patients. Mechanisms by which OSA therapy with CPAP can improve cough includes beneficial effects on reflux and airway inflammation. The aim of this study is to definitively establish that CPAP therapy for treatment of OSA in chronic cough patients improves cough. While these patients with chronic cough are not routinely screened and treated for OSA, this study aims to evaluate these chronic cough patients with screening questionnaires for OSA and if necessary with polysomnography and randomize them to either CPAP or sham CPAP for 6 weeks.

NCT ID: NCT01865422 Completed - Chronic Cough Clinical Trials

French Linguistic and Metric Validations of Parent-proxy QOL Chronic Cough Specific Questionnaire (PC-QOL)

PC-QOL
Start date: May 2013
Phase: N/A
Study type: Interventional

Cough is one of the most common reasons for consultation. Even if cough is a non-specific symptom, it can be the first sign of a chronic pathology. Several studies have demonstrated that chronic cough causes quality-of-life (QoL) impairment. Physicians' incapability to evaluate cough impact and patients' QoL has been documented. Therefore, a parent-proxy QoL chronic cough specific questionnaire (PC-QOL) has been developed and validated by Chang A. B. Objective : The aim of the study is to validate the French version of the PC-QoL, a parent-proxy QoL chronic cough specific questionnaire. Methods : Linguistic validation will be performed using backward/forward translation guidelines, and cognitive debriefing by 10 parents. Psychometric validation will be tested in 150 patients. Inclusion criteria are: patients with a diagnosis of chronic cough (> 4 weeks); 18 years of age or younger; all etiologies excepting cystic fibrosis. Informed consent from parents will be obtained. At enrollement, each parent will fulfill the PC-QOL questionnaire and two cough-related measures (visual analogue score, verbal category descriptive). Clinical data (medical history, physical examination) will be collected. Children QoL will be assessed using VSPA, Kidscreen and Qualin questionnaires. For assessing reproductibility and sensitivity to change, parents will be retested 7 and 21 days later. Content validity, construct's validity, external validity and instrument's reliability will be explored.

NCT ID: NCT01777867 Completed - Clinical trials for Gastroesophageal Reflux Disease

Cough Reflex Sensitivity and Bronchial Hyper-responsiveness

Start date: December 2012
Phase: N/A
Study type: Observational

The aim of this study is to provide pilot data on the possible gastrointestinal predictors of respiratory hyper-responsiveness and how these relate to the clinical sub-types of gastroesophageal reflux disease (GERD) and visceral acid hypersensitivity.

NCT ID: NCT01566968 Completed - Healthy Clinical Trials

Novel Endpoints in Cough Challenge Testing

NEAT
Start date: January 2011
Phase: N/A
Study type: Observational

The sensitivity of a person's cough reflex can be measured by getting them to breathe in (inhale) irritant chemicals. There are different methods by which subjects are asked to inhale these chemicals, either by taking one deep breath in, or by asking them to just continue to take a number of breaths. The purpose of this clinical research study is to see if the coughing responses are different in healthy people and people with respiratory problems that make them cough when they are given these chemicals in these two methods.